Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
What it found
Results are posted in the registry, but without a statistical test of the main measure. See the numbers below.
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Results by group
Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported
14 Days
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| Number of Reactions for Standard Infusion | 0 infusion reactions | 19 | |
| Number of Reactions for Rapid Infusion | 0 infusion reactions | 19 |
Number of Reactions for Standard Infusion
Number of Reactions for Rapid Infusion
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| Rituximab Infusion | 19 | 0 (0.0%) | 0 |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported
14 Days
SafetyGrade of Infusion Related Reactions With Rapid Infusion Will be Reported
14 Days
Safety
Other measures (1)
Change in Chair Time With Rapid Infusion Will be Reported
14 Days
Who could take part
MS (type not specified) · 18 to 80
Show the full criteria
Inclusion criteria
* Autoimmune patient at Wake Forest Baptist Health that is eligible for rituximab therapy * Tolerate the standard infusion rituximab with ≤ grade 2 hypersensitivity reaction * Consent to participate in the rapid infusion study * Age ≥ 18 years ≤ 80 years
Exclusion criteria
* Tolerate the standard infusion rituximab with ≥ grade 3 hypersensitivity reaction * Neurocognitive impairment (i.e. dementia, Alzheimers, et al)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to evaluate the impact of rapid infusion rituximab on the incidence of infusion-related reactions in patients with Autoimmune Diseases.
Papers
Loading reviews and guidelines…
Related trials
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory
Phase 1 · Not yet recruiting
Still running
- Study of an On-Body Injection System for Home Use of Ocrelizumab in Pe
Phase 3 · Running, not recruiting
Still running
- A Study of C-CAR168 in the Treatment of Central Nervous System Autoimm
Phase 1 · Not yet recruiting
Still running
- Immune System Effects in Children Born to Women With Multiple Sclerosi
Not yet recruiting
Still running
- Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue
Not a drug-phase study · Not yet recruiting
Still running
- B-cell Depletion in Offspring to Women With MS Under Immunomodulatory
Status unknown
No results found
History
Started
Feb 2013
Main results due
Aug 2014
Finished
Aug 2014
Results posted
Sept 2017